Berry Genomics Co.,Ltd (SHE:000710)
China · Delayed Price · Currency is CNY 12.28
+0.07 (0.57%)
Feb 4, 2026, 3:04 PM CST
Berry Genomics Co.,Ltd Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 921.68 | 1,059 | 1,129 | 1,343 | 1,370 | 1,504 |
Other Revenue | 19.47 | 19.47 | 21.92 | 24.64 | 52.43 | 36.1 |
| 941.16 | 1,078 | 1,151 | 1,368 | 1,422 | 1,540 | |
Revenue Growth (YoY) | -15.09% | -6.36% | -15.83% | -3.81% | -7.67% | -4.78% |
Cost of Revenue | 555.63 | 603.72 | 668.26 | 821.85 | 827.75 | 760.94 |
Gross Profit | 385.52 | 474.44 | 483.16 | 546.15 | 594.43 | 779.45 |
Selling, General & Admin | 334.44 | 357.18 | 404.55 | 463.21 | 456.17 | 403.15 |
Research & Development | 115.68 | 95.42 | 110.01 | 106.74 | 128.23 | 125.8 |
Other Operating Expenses | 8.49 | 10.64 | 4.67 | 3.76 | 2.84 | 0.31 |
Operating Expenses | 584.54 | 593.91 | 682 | 671.71 | 640.85 | 560.85 |
Operating Income | -199.01 | -119.47 | -198.84 | -125.56 | -46.41 | 218.6 |
Interest Expense | -10.32 | -9.83 | -16.35 | -17.64 | -20.3 | -15.34 |
Interest & Investment Income | 9.13 | 3.52 | 2.64 | 2.36 | 5.05 | 44.05 |
Currency Exchange Gain (Loss) | -0.77 | -0.77 | -0.55 | -1.62 | 0.38 | -1.09 |
Other Non Operating Income (Expenses) | -2.65 | -2.59 | -0.37 | 2.79 | -5.26 | -7.34 |
EBT Excluding Unusual Items | -203.63 | -129.14 | -213.47 | -139.66 | -66.54 | 238.88 |
Gain (Loss) on Sale of Investments | -28.94 | -40.18 | -82.67 | -144.31 | -49.13 | - |
Gain (Loss) on Sale of Assets | -3.46 | 1.74 | -0.01 | -0.35 | 0.26 | -0.45 |
Asset Writedown | -0.65 | -0.65 | -159.38 | -0.07 | -5.16 | -0.02 |
Other Unusual Items | -3.65 | -2.53 | 2.12 | 8.02 | 0.19 | 6.93 |
Pretax Income | -240.34 | -170.76 | -453.42 | -276.37 | -120.38 | 245.34 |
Income Tax Expense | 12.2 | 17.42 | -28.16 | -29.98 | -10.52 | 39.65 |
Earnings From Continuing Operations | -252.54 | -188.18 | -425.27 | -246.4 | -109.86 | 205.69 |
Minority Interest in Earnings | -2.84 | -4.25 | -1.93 | -2.53 | -0.96 | 4.97 |
Net Income | -255.38 | -192.43 | -427.2 | -248.93 | -110.82 | 210.67 |
Net Income to Common | -255.38 | -192.43 | -427.2 | -248.93 | -110.82 | 210.67 |
Net Income Growth | - | - | - | - | - | -46.07% |
Shares Outstanding (Basic) | 354 | 354 | 354 | 307 | 357 | 357 |
Shares Outstanding (Diluted) | 354 | 354 | 354 | 307 | 357 | 357 |
Shares Change (YoY) | 0.34% | 0.00% | 15.04% | -14.03% | 0.12% | 0.55% |
EPS (Basic) | -0.72 | -0.54 | -1.21 | -0.81 | -0.31 | 0.59 |
EPS (Diluted) | -0.72 | -0.54 | -1.21 | -0.81 | -0.31 | 0.59 |
EPS Growth | - | - | - | - | - | -46.36% |
Free Cash Flow | -44.28 | 31.22 | 55.91 | -52.13 | -242.66 | 48.76 |
Free Cash Flow Per Share | -0.13 | 0.09 | 0.16 | -0.17 | -0.68 | 0.14 |
Gross Margin | 40.96% | 44.01% | 41.96% | 39.92% | 41.80% | 50.60% |
Operating Margin | -21.15% | -11.08% | -17.27% | -9.18% | -3.26% | 14.19% |
Profit Margin | -27.13% | -17.85% | -37.10% | -18.20% | -7.79% | 13.68% |
Free Cash Flow Margin | -4.71% | 2.90% | 4.86% | -3.81% | -17.06% | 3.17% |
EBITDA | -141.22 | -43.23 | -98 | -33.42 | 50.94 | 295.5 |
EBITDA Margin | -15.00% | -4.01% | -8.51% | -2.44% | 3.58% | 19.18% |
D&A For EBITDA | 57.79 | 76.24 | 100.84 | 92.13 | 97.35 | 76.9 |
EBIT | -199.01 | -119.47 | -198.84 | -125.56 | -46.41 | 218.6 |
EBIT Margin | -21.15% | -11.08% | -17.27% | -9.18% | -3.26% | 14.19% |
Effective Tax Rate | - | - | - | - | - | 16.16% |
Revenue as Reported | 941.16 | 1,078 | 1,151 | 1,368 | 1,422 | 1,540 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.